| 66 | 0 | 26 |
| 下载次数 | 被引频次 | 阅读次数 |
“两个重构”理论框架通过重构中西医结合诊疗体系,建立“分类-分期-分证”标准路径,提高了疾病识别精度和全程干预能力;通过重构现代本草体系,创新性融合中药传统功效与现代药理作用,形成“态靶同调”精准用药模式,并构建方药量效理论体系,增强了干预的靶向性和剂量精确性。“两个重构”理论框架是提高临床疗效的关键,其能够实现态、靶精准锁定与定向干预;可前移防治关口,贯通疾病全周期管理;助力构建标准化诊疗范式,确保疗效稳定、可重复、可评估;突破辨证局限,推动中医药诊疗领域的拓展。“两个重构”理论框架是推动中医药创新的系统路径,可为推动中西医结合高质量发展提供参考。
Abstract:By reconstructing the integrated Chinese and western medicine diagnostic and treatment system, the "Two Reconstructions" theoretical framework establishes a standardized pathway of "classification-staging-syndrome differentiation", which improves the accuracy of disease identification and strengthens the capacity for full-course intervention; in addition, by reconstructing the modern materia medica system, it innovatively integrates the traditional properties and efficacy of Chinese herbal medicinals with modern pharmacological mechanisms, forming a "state-target co-regulation" precise medication model, and builds a dose-effect theoretical system for prescriptions and medicinals, thereby enhancing both the targeting accuracy and dosage precision of therapeutic interventions. The "Two Reconstructions" theorecitcal framework is a key strategy for enhancing clinical efficacy. It can precisely identify "states" and "targets" for directed intervention, shift the focus of prevention and treatment earlier to enable full-cycle management, establish standardized paradigms for reproducible and evaluable efficacy, and expand the scope of clinical practice to address conditions without typical syndromes and critical illnesses. As a systematic pathway for innovation in TCM, this theoretical framework provides valuable insights and references for promoting the high-quality development of integrative Chinese and western medicine.
[1]王翼天,仝小林.分类、分期、分证思想对慢性病中医理论构建的启示[J].中医杂志,2017,58(24):2091-2094.
[2]仝小林.关于“重构现代中医本草体系”的设想及建议[J].吉林中医药,2023,43(1):1-4.
[3]丁齐又,赵林华,宋斌,等.两个重构:中医药传承创新发展的重要路径[J].中医杂志,2023,64(9):865-869.
[4]刘桂芳,刘文科,姬航宇,等. 2型糖尿病中医诊疗思路[J].中医杂志,2011,52(14):1243-1245.
[5]仝小林.态靶医学:中医未来发展之路[J].中国中西医结合杂志,2021,41(1):16-18.
[6]宋珏娴,傅晓燕,仝小林.现代医学背景下中医诊疗体系的重构[J].中医杂志,2018,59(1):6-9.
[7]杨映映,罗金丽,李青伟,等.现代中医疫病诊疗体系的构建[J/OL].南京中医药大学学报.(2025-06-17)[2025-09-07]. https://link. cnki. net/urlid/32. 1247. R. 20250617.0901. 002.
[8]郑玉娇,苟筱雯,逄冰,等.“糖络病”学说及其诊疗要点发微[J].中医杂志,2019,60(22):1920-1923.
[9]仝小林,刘文科,王佳,等.糖尿病郁热虚损不同阶段辨治要点及实践应用[J].吉林中医药,2012,32(5):442-444.
[10]马伯艳,李寒,李云凤,等.黄连及其有效成分降糖作用的研究进展及量效关系[J].中成药,2019,41(12):2970-2973.
[11]张海宇,张湘苑,陈科宇,等.重构本草:茺蔚子[J].长春中医药大学学报,2023,39(1):1-4.
[12]董立硕,李青伟,张莉莉,等.基于态靶辨治选方用药的思路与临床应用[J].中医杂志,2023,64(3):250-254.
[13]仝小林,穆兰澄,姬航宇,等.《伤寒论》药物剂量考[J].中医杂志,2009,50(4):368-372.
[14]仝小林.方药量效学[M]. 2版.北京:科学出版社,2015.
[15]仝小林.糖络杂病论[M]. 3版.北京:科学出版社,2020:22-23.
[16]GAO Z, ZHANG W, HE L, et al. Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints Faecalibacterium as key gut bacteria in alleviating hyperglycemia[J]. Precis Clin Med,2024,7(1):pbae003.
[17]赵林华,连凤梅,姬航宇,等.仝小林教授运用不同剂量葛根芩连汤治疗2型糖尿病验案[J].中国实验方剂学杂志,2011,17(4):249-251.
[18]魏秀秀,仝小林,杨映映,等.仝小林院士辨治高血压病“三期五态”新视角[J].中医学报,2020,35(1):90-94.
[19]彭红叶,鲁春丽.主动健康视角下糖尿病前期中西医结合治疗和管理的现状与挑战[J].中国全科医学,2025,28(13):1573-1582,1606.
[20]张建伟.浅析当代火神派学术思想差异[J].中国中医基础医学杂志,2013,19(12):1385-1387.
[21]常俊杰,刘亦冰,戴文昊,等.孟河医派费氏治疗痹证用药规律研究[J].中药药理与临床,2023,39(4):102-106.
[22]中华中医药学会.糖尿病中医防治指南[M].北京:中国中医药出版社,2007.
[23]仝小林.糖尿病中医药临床循证实践指南[M].北京:科学出版社,2016.
[24]世界中医药学会联合会.国际中医药糖尿病诊疗指南[M].北京:人民卫生出版社,2017.
[25]顾成娟,赵晓华,赖杏荣,等.土茯苓、威灵仙、萆薢治疗高尿酸血症:仝小林三味小方撷萃[J].吉林中医药,2020,40(12):1556-1558.
基本信息:
DOI:10.13288/j.11-2166/r.2025.23.001
中图分类号:R242
引用信息:
[1]胡东森,赵林华,谢鹏飞,等.“两个重构”理论框架对提高中医临床疗效的作用[J].中医杂志,2025,66(23):2401-2405.DOI:10.13288/j.11-2166/r.2025.23.001.
基金信息:
国家科技重大专项(2023ZD0509300); 中华中医药学会青年人才托举工程(CACM-2023-QNRC2-A08); 中国中医科学院科技创新工程(CI2023C024YL); 中国中医科学院广安门医院护航工程(骨干人才培养项目)(GAMHH9324025); 深圳市“医疗卫生三名工程”项目(SZZYSM202202010)